Methods for determining whether a patient suffering from rhabdomyolysis achieves a response with a TLR9 antagonist

US11473145B2 · kind B2 · utility

Assignees

• INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) · FR
• FOUNDATION IMAGING · US
• ASSISTANCE PUBLIQUE—HÔPITAUX DE PARIS (APHP) · FR
• CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE · FR
• UNIVERSITÉ PARIS CITÉ · FR

Inventors

• Pascale DE LONLAY-DEBENEY · Paris, FR
• Peter VAN ENDERT · Paris, FR
• Marine MADRANGE · Paris, FR
• Yamina Hamel · Paris, FR
• François-Xavier Mauvais · Paris, FR

Key dates

• Filing date: Jul 26, 2018
• Grant date: Oct 18, 2022
• Expiry date: Mar 6, 2039

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2800/52
• WIPO field: Biotechnology
• WIPO sector: Chemistry

Abstract

The inventors initially participated to the identification of LPIN1 mutations as a cause for massive rhabdomyolysis episodes in children, triggered by febrile illness. The inventors have suggested that TLR9 antagonists would be suitable for the treatment of rhabdomyolysis (WO2017085115). The inventors thus treated 2 patients with lipin-1 disease by a TRL9 antagonist (hydroxychloroquine). They showed that the accumulation of mtDNA in plasma of the two patients before treatment decreases under treatment. When the treatment was stopped, the accumulation of mtDNA reappeared, then normalized when treatment was resumed. Accordingly, the present invention relates to a method for determining whether a patient suffering from rhabdomyolysis achieves a response with a TLR9 antagonist comprising determining the amount of mitochondrial DNA (mtDNA) in a blood sample obtained from the patient (e.g. by PCR).